“…It is important to mention that congestive heart failure (translated as myocardial infarction) can induce cardiomyocyte cell death and result in a decrease of cardiac work [3 -5]. Some drugs are used for the treatment of this clinical pathology, such as angiotensin-converting-enzyme inhibitors [6], β 1 -adrenergic agonist or β 1 -adrenergic blockers [7], diuretics [8], angiotensin-receptor inhibitors [9], calcium sensitizer [10], phosphodiesterase III inhibitors [11], ATP-ase inhibitors [12] and others. However, some of these drugs can produce adverse effects [13 -18]; therefore, in the search for a new drug for the treatment of heart failure and ischemia-reperfusion injury, several drugs have been developed such as MK-7145 (potassium channel inhibitor) [19], some heteroaryl-substituted naphthalenes (CYP11B2 inhibitors) [20,21], BAY-1021189 (guanylate cyclase stimulator) [22], N-benzylcarboxamide (G-protein-coupled receptor kinase 2 inhibitor) [23], a naphthalene-prazosin derivative (calcium channels activation) [24], a guanidine analog (sodiumhydrogen exchanger isoform inhibitor) and others.…”